Journal article
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial).
Abstract
Rationale: Chronic cough remains a major and often debilitating symptom for patients with idiopathic pulmonary fibrosis (IPF). In a phase 2A study, inhaled RVT-1601 (cromolyn sodium) reduced daytime cough and 24-hour average cough counts in patients with IPF. Objectives: To determine the efficacy, safety, and optimal dose of inhaled RVT-1601 for the treatment of chronic cough in patients with IPF. Methods: In this multicenter, randomized, …
Authors
Martinez FJ; Wijsenbeek MS; Raghu G; Flaherty KR; Maher TM; Wuyts WA; Kreuter M; Kolb M; Chambers DC; Fogarty C
Journal
American Journal of Respiratory and Critical Care Medicine, Vol. 205, No. 9, pp. 1084–1092
Publisher
American Thoracic Society
Publication Date
May 1, 2022
DOI
10.1164/rccm.202106-1485oc
ISSN
1073-449X